Annotation Detail
Information
- Associated Genes
- PDGFRA
- Associated Variants
- PDGFRA FIP1L1-PDGFRA
- Associated Disease
- myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1
- Source Database
- CIViC Evidence
- Description
- In a FIP1L1-PDGFRA positive eosinophil cell line growth-inhibitory effects were seen with all PDGFR-blocking agents, (ponatinib, sorafenib, masitinib, nilotinib, dasatinib, sunitinib, midostaurin) with ponatinib found to be the most potent compound.
- Variant Origin
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1777
- Gene URL
- https://civic.genome.wustl.edu/links/genes/38
- Variant URL
- https://civic.genome.wustl.edu/links/variants/574
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1
- Evidence Direction
- Supports
- Drug
- Ponatinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24407160
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ponatinib | Sensitivity | true |